SCHEMBL15613516

SCHEMBL15613516

Cn1nc(-c2ccc(Oc3cccc(COc4ccccc4C(F)(F)F)c3)cc2)c2c(N)ncnc21

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NUDT14 O95848 2/20 0.62
▸ NUDT5 Q9UKK9 2/20 0.62
▸ PIK3CD O00329 4/20 0.61
▸ PIK3CA P42336 4/20 0.61
▸ PIK3CB P42338 4/20 0.61
▸ PIK3CG P48736 4/20 0.61
▸ PRKDC P78527 4/20 0.61
▸ BTK Q06187 6/20 0.55
▸ RIPK1 Q13546 8/20 0.49
▸ ABL1 P00519 3/20 0.48
▸ SRC P12931 3/20 0.48
▸ EGFR P00533 2/20 0.48
▸ HCK P08631 2/20 0.48
▸ KDR P35968 2/20 0.48
▸ MTOR P42345 2/20 0.48
▸ EPHB4 P54760 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16886148 0.88 NUDT14 (0.67) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL15613524 0.86 BTK (0.66) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL15613508 0.86 NUDT14 (0.63) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL15613515 0.85 NUDT14 (0.64) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL15613473 0.84 BTK (0.56) NUDT14NUDT5PIK3CDPIK3CAPIK3CG
SCHEMBL15613570 0.83 PIK3CD (0.81) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL15613517 0.80 BTK (0.64) NUDT14NUDT5BTKABL1SRC
SCHEMBL19490557 0.80 BTK (0.57) BTKEGFR
SCHEMBL130529 0.79 NUDT14 (1.00) NUDT14NUDT5PIK3CDPIK3CAPIK3CB
SCHEMBL130425 0.77 PIK3CD (1.00) NUDT14NUDT5PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK NUDT14 2511/4885NUDT5 1603/4885PIK3CD 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback